British Journal of Haematology最新文献_第9页

Prognostic mutations identified by whole-exome sequencing and validation of the Molecular International Prognostic Scoring System in myelodysplastic syndromes after allogeneic haematopoietic stem cell transplantation 通过全外显子组测序确定的骨髓增生异常综合征异基因造血干细胞移植后的预后突变和国际分子预后评分系统的验证。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-08-13 DOI: 10.1111/bjh.19707

Hong Wang, Xueqian Li, Jiaqian Qi, Hong Liu, Tiantian Chu, Xiaoyan Xu, Huiying Qiu, Chengcheng Fu, Xiaowen Tang, Changgeng Ruan, Depei Wu, Yue Han

{"title":"Prognostic mutations identified by whole-exome sequencing and validation of the Molecular International Prognostic Scoring System in myelodysplastic syndromes after allogeneic haematopoietic stem cell transplantation","authors":"Hong Wang, Xueqian Li, Jiaqian Qi, Hong Liu, Tiantian Chu, Xiaoyan Xu, Huiying Qiu, Chengcheng Fu, Xiaowen Tang, Changgeng Ruan, Depei Wu, Yue Han","doi":"10.1111/bjh.19707","DOIUrl":"10.1111/bjh.19707","url":null,"abstract":"<div>\u0000 \u0000 In this study, we used the whole-exome sequencing (WES) approach to obtain genomic profiles from 92 marrow samples of myelodysplastic syndrome (MDS) patients before haematopoietic stem cell transplantation. We identified 129 mutations in 45 driver genes. Fifty-five patients (59.8%) carried at least 1 driver mutation. The splicing factor U2AF1 was the most frequently mutated in the cohort (21 cases, 23%), followed by BCOR (9 cases, 10%), ASXL1 (8 cases, 9%), TET2 (6 cases, 7%), NPM1 (5 cases, 5%), RUNX1 (5 cases, 5%), and SETBP1 (5 cases, 5%). WES also identified 49 possible oncogenic variants in six genes (PIEZO1, LOXHD1, MYH13, DNAH5, DPH1, and USH2A) that were associated with overall survival (OS) or relapse-free survival (RFS) in MDS after transplantation. Multivariate analysis showed mutations in DNAH5 and USH2A to be independent risk factors for OS. Mutations in DNAH5 and LOXHD1 were risk factors for worse RFS. The Molecular International Prognostic Scoring System retained its independent prognostic significance for RFS after multivariate analysis.\u0000 </div>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"205 5","pages":"1899-1909"},"PeriodicalIF":5.1,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141974567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effects of drone transportation on blood component quality: A prospective randomised controlled laboratory study 无人机运输对血液成分质量的影响：前瞻性随机对照实验室研究

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-08-08 DOI: 10.1111/bjh.19666

Michael Wiltshire, Jonathan Boxshall, James Milne, Katarzyna Oleniacz, Katherine Theobald, Benedict Phillips

{"title":"The effects of drone transportation on blood component quality: A prospective randomised controlled laboratory study","authors":"Michael Wiltshire, Jonathan Boxshall, James Milne, Katarzyna Oleniacz, Katherine Theobald, Benedict Phillips","doi":"10.1111/bjh.19666","DOIUrl":"10.1111/bjh.19666","url":null,"abstract":"<div>\u0000 \u0000 The use of uncrewed aerial vehicles (drones) has increased over the last decade. However, their application in healthcare has not been fully examined, in part, due to regulations preventing flight beyond the visual line of sight. This prospective randomised controlled laboratory study aimed to determine whether the in vitro quality of packed red blood cell components is maintained when transported by drone, beyond visual line of sight. Ten identical pairs of packed red blood cell units were randomly allocated to transport by drone or by ground vehicle (1:1, allocation concealment) 68 km between two hospitals in Northumbria, UK. Markers of blood component quality were compared at 8, 14, 28 and 35 days following blood unit manufacture. There was no statistical difference in haemolysis, potassium concentration, total haemoglobin, glucose and lactate, haematocrit and mean cell volume, between the two groups, up to the date of unit expiry. The temperature of the packed red blood cell units did not deviate outside the recommended 2–10°C for transportation, regardless of the allocated group. Blood component transport was faster by drone, but did not reach statistical significance. This study demonstrates the feasibility and safety of flying blood components by drone between hospitals in the United Kingdom.\u0000 </div>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"205 5","pages":"2022-2030"},"PeriodicalIF":5.1,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141905188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapy 接受放射治疗的局限期滤泡性淋巴瘤的单基因突变与预后。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-08-07 DOI: 10.1111/bjh.19698

Samantha A. Hershenfeld, Josuha W.D. Tobin, Victoria Shelton, Lourdes Calvente, Katherine Lajkosz, Ting Liu, Marianne Brodtkorb, Francesco Annibale d'Amore, Maja Ludvigsen, Tara Baetz, David LeBrun, Nathalie Johnson, Michael Crump, Michael Hong, John Kuruvilla, Rosemarie Tremblay-LeMay, Michael MacManus, Richard Tsang, David C. Hodgson, Maher K. Gandhi, Robert Kridel

{"title":"Single gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapy","authors":"Samantha A. Hershenfeld, Josuha W.D. Tobin, Victoria Shelton, Lourdes Calvente, Katherine Lajkosz, Ting Liu, Marianne Brodtkorb, Francesco Annibale d'Amore, Maja Ludvigsen, Tara Baetz, David LeBrun, Nathalie Johnson, Michael Crump, Michael Hong, John Kuruvilla, Rosemarie Tremblay-LeMay, Michael MacManus, Richard Tsang, David C. Hodgson, Maher K. Gandhi, Robert Kridel","doi":"10.1111/bjh.19698","DOIUrl":"10.1111/bjh.19698","url":null,"abstract":"Radiotherapy is routinely used for management of limited-stage follicular lymphoma (FL), yet half of patients ultimately relapse. We hypothesized that the presence of specific gene mutations may predict outcomes. We performed targeted sequencing of a 69-gene panel in 117 limited-stage FL patients treated with radiotherapy and identified recurrently mutated genes. CREBBP was most frequently mutated, and mutated CREBBP was associated with inferior progression-free survival, though not after false discovery rate adjustment. This association failed to validate in an independent cohort. We conclude that recurrent gene mutations do not predict outcomes in this setting. Alternative biomarkers may offer better prognostic insight.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"205 5","pages":"1810-1814"},"PeriodicalIF":5.1,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19698","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141900254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prenatal origin of NUTM1 gene rearrangement in infant B-cell precursor acute lymphoblastic leukaemia 婴儿 B 细胞前体急性淋巴细胞白血病中 NUTM1 基因重排的产前起源。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-08-05 DOI: 10.1111/bjh.19685

Michela Bardini, Grazia Fazio, Lilia Corral Abascal, Claus Meyer, Oscar Maglia, Simona Sala, Sonia Palamini, Stefano Rebellato, Rolf Marschalek, Carmelo Rizzari, Andrea Biondi, Giovanni Cazzaniga

引用次数: 0

Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma 原发性中枢神经系统淋巴瘤老年患者联合应用利妥昔单抗和甲氨蝶呤后再应用利妥昔单抗和阿糖胞苷。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-08-05 DOI: 10.1111/bjh.19659

Jun Ho Yi, Seok Jin Kim, Deok-Hwan Yang, Young Rok Do, Jong Ho Won, Dongwon Baek, Ho Jin Shin, Dae Sik Kim, Hyo Jung Kim, Ka-won Kang, Sung Hwa Bae, Ji-Hyun Kwon, Jung Hye Kwon, Byeong Bae Park, Won Seog Kim

{"title":"Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma","authors":"Jun Ho Yi, Seok Jin Kim, Deok-Hwan Yang, Young Rok Do, Jong Ho Won, Dongwon Baek, Ho Jin Shin, Dae Sik Kim, Hyo Jung Kim, Ka-won Kang, Sung Hwa Bae, Ji-Hyun Kwon, Jung Hye Kwon, Byeong Bae Park, Won Seog Kim","doi":"10.1111/bjh.19659","DOIUrl":"10.1111/bjh.19659","url":null,"abstract":"<div>\u0000 \u0000 The optimal treatment strategy for newly diagnosed primary central nervous system lymphoma (PCNSL) has yet to be established, especially in the elderly. In the current study, we conducted a phase II study to evaluate the efficacy and safety of rituximab plus high-dose MTX followed by rituximab plus cytarabine in patients aged ≥60 years newly diagnosed with PCNSL. Patients received an induction treatment of high-dose methotrexate plus rituximab followed by two cycles of a consolidation treatment of cytarabine plus rituximab. The primary end-point was a 2-year progression-free survival (PFS) rate. A total of 35 patients were recruited, and their median age was 73 (range: 60–81). After induction treatment, the complete and partial responses (PRs) were 56% and 20% respectively. Twenty-six patients proceeded to the consolidation treatment; the complete and PRs were 59% and 9% respectively. After a median follow-up duration of 36.0 months, the 2-year PFS rate was 58.7%. Treatment was generally well-tolerated as only three patients were withdrawn from the study due to toxicity, and no treatment-related mortality was reported. The 2-year overall survival rate was 77.9%. The current study may suggest the feasibility of administering high-dose MTX plus cytarabine in PCNSL patients aged ≥60 years and the potential role of additive rituximab.\u0000 </div>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"205 5","pages":"1773-1781"},"PeriodicalIF":5.1,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting CD25+ lymphoma cells with the antibody–drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents 用抗体-药物共轭物卡米单抗泰西林作为单药或与靶向药物联用，靶向 CD25+ 淋巴瘤细胞。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-07-30 DOI: 10.1111/bjh.19658

Filippo Spriano, Chiara Tarantelli, Luciano Cascione, Eugenio Gaudio, Gaetanina Golino, Lorenzo Scalise, Maria Teresa Cacciapuoti, Emanuele Zucca, Anastasios Stathis, Patrick H. Van Berkel, Giorgio Inghirami, Francesca Zammarchi, Francesco Bertoni

{"title":"Targeting CD25+ lymphoma cells with the antibody–drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents","authors":"Filippo Spriano, Chiara Tarantelli, Luciano Cascione, Eugenio Gaudio, Gaetanina Golino, Lorenzo Scalise, Maria Teresa Cacciapuoti, Emanuele Zucca, Anastasios Stathis, Patrick H. Van Berkel, Giorgio Inghirami, Francesca Zammarchi, Francesco Bertoni","doi":"10.1111/bjh.19658","DOIUrl":"10.1111/bjh.19658","url":null,"abstract":"Camidanlumab tesirine (ADCT-301) is a CD25-specific antibody-drug conjugate (ADC) employing SG3199, a highly cytotoxic DNA minor groove cross-linking pyrrolobenzodiazepine dimer. The ADC has shown early clinical antitumour activity in various cancers, including B- and T-cell lymphomas. We assessed its preclinical activity as a single agent in 57 lymphoma cell lines and in combination with selected drugs in T-cell lymphoma-derived cell lines. Cells were exposed to increasing concentrations of the ADC or SG3199 for 96 h, followed by an MTT proliferation assay. CD25 expression was measured at cell surface and RNA levels. Experiments with PDX-derived cell lines were used for validation studies. Camidanlumab tesirine presented more potent single agent in vitro cytotoxic activity in T- than B-cell lymphomas. In vitro activity was correlated with CD25 cell surface and RNA expression. In vitro activity was correlated with CD25 cell surface and RNA expression. When camidanlumab tesirine-containing combinations were evaluated in four T-cell lymphoma models, the most active partners were everolimus, copanlisib, venetoclax, vorinostat, and pralatrexate, followed by bortezomib, romidepsin, bendamustine, and 5-azacytidine. The strong camidanlumab tesirine single-agent anti-lymphoma activity and the in vitro synergisms with targeted agents identify potential combination partners for future clinical studies.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"205 5","pages":"1873-1882"},"PeriodicalIF":5.1,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19658","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141854340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis 新确诊的急性髓性白血病患者接受文尼他克加阿扎胞苷治疗（无论有无抗真菌预防）时的真菌感染频率。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-07-23 DOI: 10.1111/bjh.19670

Barbora Weinbergerová, Jiří Mayer, Tomáš Kabut, Wolfgang R. Sperr, Jana Števková, Anna Jonášová, Martin Čerňan, Susanne Herndlhofer, Iveta Oravcová, Jiří Šrámek, Jan Novák, Radka Štěpánová, Tomáš Szotkowski, Luboš Drgoňa, Pavel Žák, Peter Valent

{"title":"Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis","authors":"Barbora Weinbergerová, Jiří Mayer, Tomáš Kabut, Wolfgang R. Sperr, Jana Števková, Anna Jonášová, Martin Čerňan, Susanne Herndlhofer, Iveta Oravcová, Jiří Šrámek, Jan Novák, Radka Štěpánová, Tomáš Szotkowski, Luboš Drgoňa, Pavel Žák, Peter Valent","doi":"10.1111/bjh.19670","DOIUrl":"10.1111/bjh.19670","url":null,"abstract":"Our observational study analysed fungal infection frequency within cohorts with versus without antifungal prophylaxis (AFP) among newly diagnosed first-line venetoclax and azacitidine (VEN + AZA)-treated acute myeloid leukaemias in Czech, Austrian and Slovak haematology centres. Among 186 patients, 85 (46%) received antifungal prophylaxis, while 101 (54%) received no prophylaxis. Fungal infections occurred in 1/85 patients with prophylaxis (1%) and 5/101 patients without prophylaxis (5%) (p = 0.222). No significant difference was recorded between cohorts with and without AFP in terms of death rate (p = 0.296) and overall survival (p = 0.844). In conclusion, most infections were not severe, developing during the first treatment-cycle and did not affect patients' overall outcome.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"205 5","pages":"1746-1750"},"PeriodicalIF":5.1,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19670","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141750633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improving disease-specific survival for patients with Sezary syndrome in the modern era of systemic therapies 在现代系统疗法时代，提高塞扎里综合征患者的疾病特异性生存率。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-07-19 DOI: 10.1111/bjh.19647

Belinda A. Campbell, Gabor Dobos, Zahra Haider, Martine Bagot, Felicity Evison, Carrie van der Weyden, Chris McCormack, Caroline Ram-Wolff, Maryam Miladi, H. Miles Prince, Julia J. Scarisbrick

{"title":"Improving disease-specific survival for patients with Sezary syndrome in the modern era of systemic therapies","authors":"Belinda A. Campbell, Gabor Dobos, Zahra Haider, Martine Bagot, Felicity Evison, Carrie van der Weyden, Chris McCormack, Caroline Ram-Wolff, Maryam Miladi, H. Miles Prince, Julia J. Scarisbrick","doi":"10.1111/bjh.19647","DOIUrl":"10.1111/bjh.19647","url":null,"abstract":"Traditionally, Sezary syndrome (SS) has been associated with few therapeutic options and poor prognosis, with 5-year disease-specific survival (DSS) less than one-third in historical cohorts. However, newer therapies and combinations are associated with impressive time-to-next-treatment (TTNT), particularly allogeneic stem-cell transplantation (AlloSCT) and combination therapies notably those including extracorporeal photopheresis. In this multicentre, international study, we explored the prognostic outcomes of 178 patients exclusively managed for SS, diagnosed between 2012 and 2020, and treated in the modern therapeutic era. In this cohort, 58 different therapies were delivered, with 13.5% of patients receiving AlloSCT. Long-term survival exceeded historical reports with 5-year DSS and OS of 56.4% and 53.4% respectively. In those receiving AlloSCT, prognosis was excellent: 5-year DSS and OS were 90.5% and 78.0% respectively. Confirming the results from the Cutaneous Lymphoma International Consortium (CLIC), LDH and LCT had significant prognostic impact. Unlike earlier studies, stage did not have prognostic impact; we speculate that greater relative benefit favours patients with extensive lymphomatous nodal disease (Stage IVA2) compared to historical reports. For patients ineligible for AlloSCT, the prognosis remains relatively poor (5-year DSS 51.4% and OS 49.6%), representing ongoing unmet needs for more effective novel agents and investigation of improved therapeutic combinations.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"205 5","pages":"1825-1829"},"PeriodicalIF":5.1,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19647","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141730840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Indolent lymphoma care delivery and outcomes during the COVID-19 pandemic in Ontario, Canada 加拿大安大略省新冠肺炎大流行期间的Indolent淋巴瘤护理提供和结果。

IF 6.5 2区医学

British Journal of Haematology Pub Date : 2023-10-27 DOI: 10.1111/bjh.19166

Inna Y. Gong, Anca Prica, Zharmaine Ante, Andrew Calzavara, Monika K. Krzyzanowska, Simron Singh, Adam Suleman, Matthew C. Cheung, Michael Crump

{"title":"Indolent lymphoma care delivery and outcomes during the COVID-19 pandemic in Ontario, Canada","authors":"Inna Y. Gong, Anca Prica, Zharmaine Ante, Andrew Calzavara, Monika K. Krzyzanowska, Simron Singh, Adam Suleman, Matthew C. Cheung, Michael Crump","doi":"10.1111/bjh.19166","DOIUrl":"10.1111/bjh.19166","url":null,"abstract":"<div>\u0000 \u0000 The treatment pattern and outcomes in patients with indolent B-cell lymphoma treated during the coronavirus disease 2019 (COVID-19) pandemic period compared to the prepandemic period are unclear. This was a retrospective population-based study using administrative databases in Ontario, Canada (follow-up to 31 March 2022). The primary outcome was treatment pattern; secondary outcomes were death, toxicities, healthcare utilization (emergency department [ED] visit, hospitalization) and SARS-CoV-2 outcomes. Adjusted hazard ratios (aHR) from Cox proportional hazards models were used to estimate associations. We identified 4143 patients (1079 pandemic, 3064 prepandemic), with a median age of 69 years. In both time periods, bendamustine (B) + rituximab (BR) was the most frequently prescribed regimen. During the pandemic, fewer patients received R maintenance or completed the full 2-year course (aHR 0.81, 95% CI 0.71–0.92, p = 0.001). Patients treated during the pandemic had less healthcare utilization (ED visit aHR 0.77, 95% CI 0.68, 0.88, p < 0.0001; hospitalization aHR 0.81, 95% CI 0.70–0.94, p = 0.0067) and complications (infection aHR 0.69, 95% CI 0.57–0.82, p < 0.0001; febrile neutropenia aHR 0.66, 95% CI 0.47–0.94, p = 0.020), with no difference in death. Independent of vaccination, active rituximab use was associated with a higher risk of COVID-19 complications. Despite similar front-line regimen use, healthcare utilization and admissions for infection were less in the pandemic cohort.\u0000 </div>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"204 3","pages":"805-814"},"PeriodicalIF":6.5,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54227107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine–rituximab 接受苯达莫司汀-利妥昔单抗治疗的未经治疗的老年套细胞淋巴瘤患者的临床参数和生物标志物的评估。

IF 6.5 2区医学

British Journal of Haematology Pub Date : 2023-10-25 DOI: 10.1111/bjh.19153

Colleen A. Ramsower, Allison Rosenthal, Ryan S. Robetorye, Raphael Mwangi, Matthew Maurer, Diego Villa, Tim McDonnell, Andrew Feldman, Jonathon B. Cohen, Thomas Habermann, Elias Campo, Guillem Clot, Marco M. Bühler, Marta Kulis, Jose Ignacio Martin-Subero, Eva Giné, James R. Cook, Brian Hill, Philipp W. Raess, Klaus H. Beiske, Alexander Reichart, Sylvia Hartmann, Harald Holte, David Scott, Lisa Rimsza

{"title":"Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine–rituximab","authors":"Colleen A. Ramsower, Allison Rosenthal, Ryan S. Robetorye, Raphael Mwangi, Matthew Maurer, Diego Villa, Tim McDonnell, Andrew Feldman, Jonathon B. Cohen, Thomas Habermann, Elias Campo, Guillem Clot, Marco M. Bühler, Marta Kulis, Jose Ignacio Martin-Subero, Eva Giné, James R. Cook, Brian Hill, Philipp W. Raess, Klaus H. Beiske, Alexander Reichart, Sylvia Hartmann, Harald Holte, David Scott, Lisa Rimsza","doi":"10.1111/bjh.19153","DOIUrl":"10.1111/bjh.19153","url":null,"abstract":"<div>\u0000 \u0000 Mantle cell lymphoma (MCL) is clinically and biologically heterogeneous. While various prognostic features have been proposed, none currently impact therapy selection, particularly in older patients, for whom treatment is primarily dictated by age and comorbidities. Herein, we undertook a comprehensive comparison of clinicopathological features in a cohort of patients 60 years and older, uniformly treated with bendamustine and rituximab, with a median survival of >8 years. The strongest prognostic indicators in this cohort were a high-risk call by a simplified MCL international prognostic index (s-MIPI) (HR: 3.32, 95% CI: 1.65–6.68 compared to low risk), a high-risk call by MCL35 (HR: 10.34, 95% CI: 2.37–45.20 compared to low risk) and blastoid cytology (HR: 4.21, 95% CR: 1.92–9.22 compared to classic). Patients called high risk by both the s-MIPI and MCL35 had the most dismal prognosis (HR: 11.58, 95% CI: 4.10–32.72), while those with high risk by either had a moderate but clinically relevant prognosis (HR: 2.95, 95% CI: 1.49–5.82). A robust assay to assess proliferation, such as MCL35, along with stringent guidelines for cytological evaluation of MCL, in combination with MIPI, may be a strong path to risk-stratify older MCL patients in future clinical trials.\u0000 </div>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"204 1","pages":"160-170"},"PeriodicalIF":6.5,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19153","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50159982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0